Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;34(1):1307-1313.
doi: 10.1080/14756366.2019.1594802.

Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells

Roberta Ettari  1 , Giovanni Pallio  2 , Gabriele Pizzino  2 , Natasha Irrera  2 , Maria Zappalà  1 , Santina Maiorana  1 , Carla Di Chio  1 , Domenica Altavilla  3 , Francesco Squadrito  2 , Alessandra Bitto  2
Affiliations

Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells

Roberta Ettari et al. J Enzyme Inhib Med Chem. 2019 Dec.

Abstract

Proteasome inhibition is a promising strategy for the treatment of multiple myeloma; unfortunately, this disease is often associated with an increasing chemoresistance. One novel approach may be to target the immunoproteasome, a proteasomal isoform mainly present in cells of hematopoietic origin. We investigated the activity of a panel of amides against immunoproteasome core particles as potential agents for the treatment of multiple myeloma (MM). Amide 6 showed an ideal profile since it was able to inhibit both the chymotrypsin-like activities of the immunoproteasome with Ki values of 4.90 µM and 4.39 µM for β1i and β5i, respectively, coupled with an EC50 =17.8 µM against MM.1R cells. Compound 6 inhibited also ubiquitinated protein degradation and was able to act on different phases of MM cell cycle reducing the levels of cyclin A/CDK1, cyclin B/CDK1 and cyclin D/CDK4/6 complexes, which turns in cell cycle arrest.

Keywords: Immunoproteasome; cyclins; multiple myeloma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Structure of peptidomimetic amides 1–6.
Figure 2.
Figure 2.
Effects of several concentrations of compounds 5 and 6 on vitality of MM.1R cells. Each point is obtained from the mean of 5 separate experiments.
Figure 3.
Figure 3.
Effects of compounds 5–6, in panels A and B respectively, on ubiquitin accumulation in MM.1R cells. The upper blots depicts ubiquitin (10 KDa) and the lower β-actin (45 KDa). Each bar is obtained from the mean of 3 separate experiments. *p < .005 versus ctrl.
Figure 4.
Figure 4.
Figures depict western blots results relatively to cyclin A and CDK1, both normalized for β-actin (lower bands); panels A and B show results for compound 5 and 6, respectively. Each bar is obtained from the mean of 3 separate experiments. *p < .005 versus ctrl; #p < .05 versus ctrl.
Figure 5.
Figure 5.
Figures depict western blots results relatively to cyclin B and CDK1, both normalized for β-actin (lower bands); panels A and B show results for compound 5 and 6, respectively. Each bar is obtained from the mean of 3 separate experiments.
Figure 6.
Figure 6.
Figures depict western blots results relatively to cyclin D1 and CDK4/6, both normalized for β-actin (lower bands); panels A and B show results for compound 5 and 6, respectively. Each bar is obtained from the mean of 3 separate experiments.
Figure 7.
Figure 7.
Figures depict western blots results relatively to NF-kB and phospho-NF-kB, both normalized for β-actin (lower bands); panels A and B show results for compound 5 and 6, respectively. Each bar is obtained from the mean of 3 separate experiments.
Figure 8.
Figure 8.
Figures depict western blots results relatively to PARP and Caspase-3, both normalized for β-actin (lower bands); panels A and B show results for compound 5 and 6, respectively. Each bar is obtained from the mean of 3 separate experiments.
See this image and copyright information in PMC

References

    1. Micale N, Scarbaci K, Troiano V, et al. Peptide-based proteasome inhibitors in anticancer drug design. Med Res Rev 2014;34:1001–69. - PubMed
    1. Ettari R, Previti S, Bitto A, et al. Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases. Curr Med Chem 2016;23:1217–38. - PubMed
    1. Ferrington DA, Gregerson DS. Immunoproteasome: structure, function, and antigen presentation. Prog Mol Biol Transl Sci 2012;109:75–112. - PMC - PubMed
    1. Ettari R, Zappalà M, Grasso S, et al. Immunoproteasome-selective and non-selective inhibitors: a promising approach for the treatment of multiple myeloma. Pharmacol Ther 2018;182:176–92. - PubMed
    1. Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009;114:3439–47. - PubMed

MeSH terms

Substances